Abiopharma

🔍 CHASE WILLIAM J (Executive)

Company: Intellia Therapeutics, Inc. (NTLA)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Acquired 9,200 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: A | equity_swap_involved: false | shares_owned_after: 143,893.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 13,300 shares of Stock Option (right to buy) at $12.89 per share (Derivative)
  Date: 2026-06-09 | Code: A | Expires: 2036-06-08 | equity_swap_involved: false | shares_owned_after: 13,300.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
• F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.